Background: Pemetrexed plus carboplatin and paclitaxel plus carboplatin and .

In the case series by Scagliotti et al 20035, 14.1% of patients given pemetrexed

Jul 6, 2011 . At the same time, however, the use of pemetrexed has shifted from its original

Scagliotti GV et al. Phase II study of pemetrexed with and without folic acid and

Pemetrexed. Pemetrexed (Alimta). Scagliotti GV et al. Phase II study of

Why not treat this patient with pemetrexed + cisplatin given the 2-month median

May 27, 2008 . Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, . Phase II

Scagliotti's study showed that using cisplatin/pemetrexed rather than cisplatin/

Scagliotti suggestions (Click to sort alphabetically). Scagliotti stats.

Pemetrexed was subsequently approved in the second-line setting on the basis

Dr. Scagliotti Discusses the Future of Lung Cancer Therapy. Dr. Scagliotti on

Jan 15, 2005 . Giorgio Vittorio Scagliotti, Department of Clinical and Biological . and toxicity of

[9] G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter and P. Peterson et

Feb 16, 2009 . The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review

Adjei AA. Pemetrexed (Alimta): A novel multitargeted antifolate agent. Expert Rev

Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing

randomized trial of Scagliotti et al, comparing pemetrexed/cisplatin versus

Mar 1, 2005 . NEW YORK-Doublets of pemetrexed(Drug information on . said Dr. Scagliotti, of

6 days ago . The primary end point of the study was successfully met,” said Dr. Scagliotti, of

During the 12th World Conference on Lung Cancer, Scagliotti et al presented the

Apr 15, 2003 . Address reprint requests to Giorgio V. Scagliotti, MD, University of Turin, .

Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U,. Manegold C, et

Scagliotti et al. J Clin Oncol 2008. Pemetrexed 500 mg/m2 +. Cisplatin 75 mg/m2.

Jul 20, 2008 . Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin

Sep 5, 2007 . Dr. Grønberg's study was supported by Eli Lilly, which also supplied the

Scagliotti believes this information provides a way to broadly personalize

Aug 31, 2011 . Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department

Jul 20, 2008 . Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne . Phase II

More recently, in a trial published by Scagliotti et al, pemetrexed plus cisplatin

4 days ago . Scagliotti and colleagues analyzed data from two recent phase III studies of

Mar 24, 2009 . 2, Peterson P, Park K, Fosella F, Gatzemeier U, John W, Scagliotti G: Is

The differential efficacy of pemetrexed according to NSCLC histology: a review

d1. Shepherd [33]. Pemetrexed. 500 mg/m2 d1 q3w. 31 (29). 16%, 84%. 45%. 8.9

8, Article Pemetrexed: a new cytotoxic agent in the development for first-line

49: Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.

Apr 21, 2008 . (1) Scagliotti G, Purvish P, et al. Phase III study of pemetrexed plus cisplatin

With Cisplatin Plus Pemetrexed in Chemotherapy-Naive. Patients With Advanced

Mar 14, 2011 . doublets that was better than all the others,” said Dr. Scagliotti. With the advent of

Aug 31, 2011 . Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing

The Differential Efficacy of Pemetrexed According to NSCLC. Histology: A

Apr 11, 2008 . This approval - the third for pemetrexed in Europe - follows an initial positive .

Dec 1, 2008 . Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin

Jan 15, 2005 . Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien .

Scagliotti GV. Survival without toxicity for cisplatin plus pemetrexed versus

Jul 31, 2008 . for the investigators of the Italian Pemetrexed monotherapy of NSCLC group . ..

[6] P. Peterson, P. Park, F. Fossella, F. Gatzmeier, J. Ulrich and G. Scagliotti, Is

An evaluation of pemetrexed in second-line treatment of non-small cell lung

combination chemotherapy rather than as single agent. Pemetrexed

Aug 9, 2011 . Scagliotti, G (Giorgio) :: Pharmacogenomic strategies for developing . The

1: Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L

Sitemap